Evidence map›Paper›PMID 38321920›Full record

ArticlePsychiatric services (Washington, D.C.)2024

Attention-Deficit Hyperactivity Disorder Stimulant Therapy and Prescription Drug Misuse During Transition to Young Adulthood.

Sean Esteban McCabe, John E Schulenberg, Timothy E Wilens, Ty S Schepis, Kennedy S Werner, Vita V McCabe, Philip T Veliz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychiatric services (Washington, D.C.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. ADHD, substance use disorders and stimulant treatment: understanding the relationships.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2025
    Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sean Esteban McCabeCenter for the Study of Drugs, Alcohol, Smoking and Health, School of Nursing (S. E. McCabe, Wilens, Schepis, Werner, V. V. McCabe, Veliz), Institute for Social Research (S. E. McCabe, Schulenberg, Veliz), Department of Psychology (Schulenberg), and Department of Psychiatry (Werner, V. V. McCabe), University of Michigan, Ann Arbor; Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Harvard University, Boston (Wilens); Department of Psychology, Texas State University, San Marcos (Schepis).
John E SchulenbergCenter for the Study of Drugs, Alcohol, Smoking and Health, School of Nursing (S. E. McCabe, Wilens, Schepis, Werner, V. V. McCabe, Veliz), Institute for Social Research (S. E. McCabe, Schulenberg, Veliz), Department of Psychology (Schulenberg), and Department of Psychiatry (Werner, V. V. McCabe), University of Michigan, Ann Arbor; Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Harvard University, Boston (Wilens); Department of Psychology, Texas State University, San Marcos (Schepis).
Timothy E WilensCenter for the Study of Drugs, Alcohol, Smoking and Health, School of Nursing (S. E. McCabe, Wilens, Schepis, Werner, V. V. McCabe, Veliz), Institute for Social Research (S. E. McCabe, Schulenberg, Veliz), Department of Psychology (Schulenberg), and Department of Psychiatry (Werner, V. V. McCabe), University of Michigan, Ann Arbor; Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Harvard University, Boston (Wilens); Department of Psychology, Texas State University, San Marcos (Schepis).
Ty S SchepisCenter for the Study of Drugs, Alcohol, Smoking and Health, School of Nursing (S. E. McCabe, Wilens, Schepis, Werner, V. V. McCabe, Veliz), Institute for Social Research (S. E. McCabe, Schulenberg, Veliz), Department of Psychology (Schulenberg), and Department of Psychiatry (Werner, V. V. McCabe), University of Michigan, Ann Arbor; Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Harvard University, Boston (Wilens); Department of Psychology, Texas State University, San Marcos (Schepis).
Kennedy S WernerCenter for the Study of Drugs, Alcohol, Smoking and Health, School of Nursing (S. E. McCabe, Wilens, Schepis, Werner, V. V. McCabe, Veliz), Institute for Social Research (S. E. McCabe, Schulenberg, Veliz), Department of Psychology (Schulenberg), and Department of Psychiatry (Werner, V. V. McCabe), University of Michigan, Ann Arbor; Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Harvard University, Boston (Wilens); Department of Psychology, Texas State University, San Marcos (Schepis).
Vita V McCabeCenter for the Study of Drugs, Alcohol, Smoking and Health, School of Nursing (S. E. McCabe, Wilens, Schepis, Werner, V. V. McCabe, Veliz), Institute for Social Research (S. E. McCabe, Schulenberg, Veliz), Department of Psychology (Schulenberg), and Department of Psychiatry (Werner, V. V. McCabe), University of Michigan, Ann Arbor; Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Harvard University, Boston (Wilens); Department of Psychology, Texas State University, San Marcos (Schepis).
Philip T VelizCenter for the Study of Drugs, Alcohol, Smoking and Health, School of Nursing (S. E. McCabe, Wilens, Schepis, Werner, V. V. McCabe, Veliz), Institute for Social Research (S. E. McCabe, Schulenberg, Veliz), Department of Psychology (Schulenberg), and Department of Psychiatry (Werner, V. V. McCabe), University of Michigan, Ann Arbor; Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Harvard University, Boston (Wilens); Department of Psychology, Texas State University, San Marcos (Schepis).

Funding

Monitoring the Future: Drug Use & Lifestyles of American Youth (Supp1: Nicotine Pouch and E-cigarette Use Among US Adolescents: National Estimates of Brand Use and Flavor Preferences)R01DA001411 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Richard A Miech · 1985 to 2026
$144.9M
Monitoring the Future: A Cohort-Sequential Panel Study of Drug Use, Ages 19-65 - Diversity Supplement (Solberg)R01DA016575 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Megan E. Patrick · 2003 to 2026
$44.6M
Scientific/Technical CoreP2CHD041028 · NICHD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Sarah A. Burgard · 2017 to 2026
$6.5M
Trajectories of Prescription Nonmedical Drug MisuseR01DA031160 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SEAN ESTEBAN MCCABE · 2011 to 2026
$3.7M
Does Treating Young Persons Psychopathology Prevent the Onset of Opioid and other Substance Use Disorders?UH3DA050252 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI WILENS, TIMOTHY E, YULE, AMY · 2020 to 2020
$3.0M
Prescription Drug Misuse Characteristics in Adolescents and Young Adults: Influence of School EnrollmentR01DA043691 · NIDA · TEXAS STATE UNIVERSITY · PI TY Stephen SCHEPIS · 2017 to 2026
$1.8M
Longitudinal Changes in Recovery from Drug Use Disorders: A National StudyR01DA036541 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MCCABE, SEAN ESTEBAN · 2015 to 2017
$647k
NICHD NIH HHS P2C HD041028NIDA NIH HHS R01 DA001411NIDA NIH HHS R01 DA016575NIDA NIH HHS R01 DA031160NIDA NIH HHS R01 DA036541NIDA NIH HHS R01 DA043691NIDA NIH HHS UH3 DA050252
6 · The paper itself

Abstract

objectiveLimited prospective data exist about the impact of stimulant therapy for attention-deficit hyperactivity disorder (ADHD) during adolescence on the risk for later prescription drug misuse (PDM; i.e., of benzodiazepines, opioids, and stimulants).

methodsNational longitudinal multicohort panels (baseline cohort years 2005-2017) of U.S. 12th grade students (N=11,066; ages 17 and 18 years) from the Monitoring the Future study were surveyed via self-administered questionnaires and followed up biennially during young adulthood (ages 19-24). A multivariable analysis was used to assess whether adolescents' lifetime history of stimulant therapy for ADHD was associated with subsequent PDM.

resultsOverall, 9.9% of adolescents reported lifetime stimulant therapy for ADHD at ages 17 and 18. No significant differences were found in the adjusted odds of later incidence or prevalence of past-year PDM during young adulthood between adolescents with lifetime stimulant therapy and adolescents with no stimulant therapy. Over the 5-year follow-up, past-year PDM during young adulthood was most prevalent among adolescents who reported both stimulant therapy and prescription stimulant misuse (53.1%) and those who reported prescription stimulant misuse only (51.5%). Compared with adolescents in a control group without lifetime stimulant therapy or misuse, adolescents reporting prescription stimulant misuse had significantly higher adjusted odds of later incidence and prevalence of PDM during young adulthood.

conclusionsAdolescents' stimulant therapy for ADHD was not significantly associated with increased risk for later PDM during young adulthood. In contrast, adolescents' misuse of prescription stimulants strongly predicted later PDM. Monitoring adolescents for prescription stimulant misuse may help identify and mitigate the risk for future PDM.

Indexed as

Attention Deficit Disorder with HyperactivityCentral Nervous System StimulantsPrescription Drug MisuseAdolescentAdultFemaleHumansLongitudinal StudiesMaleUnited StatesYoung AdultCentral Nervous System StimulantsADHDAttention-deficit/hyperactivity disorderDrug abuseMedication misusePrescriptionStimulant

Identifiers

PMID38321920
PMCPMC11315353

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.